Last €0.10 EUR
Change Today 0.00 / 0.00%
Volume 38.8K
DNR On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 11:55 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

dendreon corp (DNR) Snapshot

Open
€0.10
Previous Close
€0.10
Day High
€0.11
Day Low
€0.10
52 Week High
12/19/13 - €2.54
52 Week Low
11/17/14 - €0.06
Market Cap
16.3M
Average Volume 10 Days
76.7K
EPS TTM
--
Shares Outstanding
158.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DENDREON CORP (DNR)

dendreon corp (DNR) Related Businessweek News

No Related Businessweek News Found

dendreon corp (DNR) Details

Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Its product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating various types of cancers. The company offers PROVENGE, an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, and castrate-resistant prostate cancer. Its product candidates under research and development includes DN24-02, an investigational active cellular immunotherapy, which is in Phase II clinical trial for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; carbonic anhydrase 9, an antigen expressed in renal cell carcinoma; carcinoembryonic antigen, an antigen expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat various types of cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington. On November 10, 2014, Dendreon Corp. along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

710 Employees
Last Reported Date: 11/10/14
Founded in 1992

dendreon corp (DNR) Top Compensated Officers

Interim Chief Financial Officer, Principal Ac...
Total Annual Compensation: $354.1K
Compensation as of Fiscal Year 2013.

dendreon corp (DNR) Key Developments

Dendreon Corp.(OTCPK:DNDN.Q) dropped from Russell 2000 Index

Dendreon Corp. will be removed from the Russell 2000 Index.

Dendreon Corp.(OTCPK:DNDN.Q) dropped from Russell 3000 Index

Dendreon Corp. will be removed from the Russell 3000 Index.

Dendreon Corp.(NasdaqGS:DNDN) dropped from NASDAQ Biotechnology Index

Dendreon Corp. will be removed from the NASDAQ Biotechnology Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DNR:GR €0.10 EUR 0.00

DNR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DNR.
View Industry Companies
 

Industry Analysis

DNR

Industry Average

Valuation DNR Industry Range
No financial data is available for DNR.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DENDREON CORP, please visit www.dendreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.